Portal:COVID-19/FeaturedPathways
From WikiPathways
(Difference between revisions)
(→SARS-CoV-2 Pathways) |
Current revision (06:30, 22 October 2023) (view source) (Added new pathway) |
||
| (6 intermediate revisions not shown.) | |||
| Line 26: | Line 26: | ||
|width=100px|{{#pwImage:Pathway:WP5038|250px||SARS-CoV-2 mitochondrial interactions}} | |width=100px|{{#pwImage:Pathway:WP5038|250px||SARS-CoV-2 mitochondrial interactions}} | ||
|width=100px|{{#pwImage:Pathway:WP5039|250px||SARS-CoV-2 Innate Immunity Evasion and Cell-specific immune response}} | |width=100px|{{#pwImage:Pathway:WP5039|250px||SARS-CoV-2 Innate Immunity Evasion and Cell-specific immune response}} | ||
| - | |||
| - | |||
|width=100px|{{#pwImage:Pathway:WP5063|250px||FOXP3 in COVID-19 (Homo sapiens)}} | |width=100px|{{#pwImage:Pathway:WP5063|250px||FOXP3 in COVID-19 (Homo sapiens)}} | ||
| + | |- | ||
|width=100px|{{#pwImage:Pathway:WP5065|250px||SARS-CoV-2 altering angiogenesis via NRP1 (Homo sapiens)}} | |width=100px|{{#pwImage:Pathway:WP5065|250px||SARS-CoV-2 altering angiogenesis via NRP1 (Homo sapiens)}} | ||
|width=100px|{{#pwImage:Pathway:WP5076|250px||Soluble ACE2-mediated cell entry of SARS-CoV-2 (Homo sapiens)}} | |width=100px|{{#pwImage:Pathway:WP5076|250px||Soluble ACE2-mediated cell entry of SARS-CoV-2 (Homo sapiens)}} | ||
| + | |width=100px|{{#pwImage:Pathway:WP5115|250px||A Network Map of SARS-CoV-2 Signaling Pathway (Homo sapiens)}} | ||
| + | |width=100px|{{#pwImage:Pathway:WP5116|250px||SARS-CoV-2 B.1.1.7 variant antagonises innate immune activation (Homo sapiens)}} | ||
| + | |- | ||
| + | |width=100px|{{#pwImage:Pathway:WP5145|250px||COVID-19 Structural coverage map (Homo sapiens)}} | ||
| + | |width=100px|{{#pwImage:Pathway:WP5146|250px||Lung Pathology of COVID-19 (Homo sapiens)}} | ||
| + | |width=100px|{{#pwImage:Pathway:WP5148|250px||Complement-mediated inflammation of pulmonary alveolus in COVID-19 (hypothetical patwhay) (Homo sapiens)}} | ||
| + | |width=100px|{{#pwImage:Pathway:WP5218|250px||Extrafollicular B cell activation by SARS-CoV-2 (Homo sapiens)}} | ||
| + | |- | ||
| + | |width=100px|{{#pwImage:Pathway:WP5255|250px||SARS-CoV-2 envelope lipid composition and human cell binding)}} | ||
| + | |width=100px|{{#pwImage:Pathway:WP5414|250px||IDO metabolic pathway)}} | ||
|} | |} | ||
| + | |||
== Other coronaviruses: MERS, SARS-CoV, etc == | == Other coronaviruses: MERS, SARS-CoV, etc == | ||
| Line 99: | Line 109: | ||
* [[Pathway:WP5038]] | * [[Pathway:WP5038]] | ||
* [[Pathway:WP5039]] | * [[Pathway:WP5039]] | ||
| - | |||
Current revision
Contents |
SARS-CoV-2 Pathways
|
Image does not exist SARS-CoV-2 and COVID-19 Pathway Collaborative project for curation of biological processes involved in the COVID-19 disease after SARS-Cov-2 infection. |
Image does not exist Hijack of Ubiquitination by SARS-CoV-2 SARS-CoV-2 includes a novel Orf10 that interacts with multiple members of the Cullin 2 ubiquitin ligase complex. |
Image does not exist Type I Interferon Induction and Signaling During SARS-CoV-2 Infection The induction and signaling of type I interferon with specific SARS-CoV-2 protein and relevant drug. |
Image does not exist COVID-19, thrombosis and anticoagulation |
|
Image does not exist Activation of NLRP3 Inflammasome by SARS-CoV-2 Orf3a from SARS-CoV has been shown to bind TRAF3 and activate the NLRP3 inflammasome. |
Image does not exist SARS-CoV-2 and Angiotensin-converting enzyme 2 (ACE2) receptor : Molecular mechanisms and potential therapeutic target |
Image does not exist COVID-19 AOP Experimental pathway to investigate overlap of virus-host interaction and adverse outcome pathways |
Image does not exist nsp9/nsp10-mediated SARS-CoV-2 pathogenesis Virus-host interactome and proteomic survey of PMBCs from COVID-19 patients reveal potential virulence factors influencing SARS-CoV-2 pathogenesis |
|
Image does not exist LDLRAD4 pathway in COVID-19 |
Image does not exist Overview of perturbations to host-cell autophagy, induced by distinct proteins of SARS-CoV-2 (Homo sapiens) |
Image does not exist STING pathway in Kawasaki-like disease and COVID-19 (Homo sapiens) |
Image does not exist RAS and Bradykinin pathways in COVID-19 (Homo sapiens) |
|
Image does not exist nsp1 from SARS-CoV-2 inhibits translation initiation in the host cell |
Image does not exist SARS-CoV-2 mitochondrial interactions |
Image does not exist SARS-CoV-2 Innate Immunity Evasion and Cell-specific immune response |
Image does not exist FOXP3 in COVID-19 (Homo sapiens) |
|
Image does not exist SARS-CoV-2 altering angiogenesis via NRP1 (Homo sapiens) |
Image does not exist Soluble ACE2-mediated cell entry of SARS-CoV-2 (Homo sapiens) |
Image does not exist A Network Map of SARS-CoV-2 Signaling Pathway (Homo sapiens) |
Image does not exist SARS-CoV-2 B.1.1.7 variant antagonises innate immune activation (Homo sapiens) |
|
Image does not exist COVID-19 Structural coverage map (Homo sapiens) |
Image does not exist Lung Pathology of COVID-19 (Homo sapiens) |
Image does not exist Complement-mediated inflammation of pulmonary alveolus in COVID-19 (hypothetical patwhay) (Homo sapiens) |
Image does not exist Extrafollicular B cell activation by SARS-CoV-2 (Homo sapiens) |
|
Image does not exist SARS-CoV-2 envelope lipid composition and human cell binding) |
Image does not exist IDO metabolic pathway) |
Other coronaviruses: MERS, SARS-CoV, etc
|
Image does not exist Coronavirus lipid metabolism Lipid metabolism alternations that are related to infection by the corona virus. |
Image does not exist Host-pathogen interaction of human corona viruses - autophagy |
Image does not exist Host-pathogen interaction of human corona viruses - apoptosis |
Image does not exist SARS coronavirus and innate immunity |
|
Image does not exist ER stress response in Coronavirus infection |
Image does not exist Downregulation of ACE2 expression by SARS-CoV infection and SARS-CoV Spike protein |
Image does not exist Host-pathogen interaction of human corona viruses - MAPK signaling |
Image does not exist Host-pathogen interaction of human corona viruses - Interferon induction |
|
Image does not exist Deregulation of the Renin Angiotensin system by Sars-CoV infection |
More about ACE2
|
Image does not exist ACE Inhibitor Pathway |
Image does not exist Metabolism of Angiotensinogen to Angiotensins (Reactome) |
Pathways from Reactome
|
Image does not exist SARS-CoV-1 Infection(Reactome) |
Image does not exist SARS-CoV-2 Infection(Reactome) |
List of featured pathways:
- Pathway:WP4846
- Pathway:WP4860
- Pathway:WP4868
- Pathway:WP4927
- Pathway:WP4876
- Pathway:WP4883
- Pathway:WP4891
- Pathway:WP4884
- Pathway:WP4904
- Pathway:WP4936
